Form 4: CalciMedica CEO Rachel Leheny Acquires 1,000 Shares of Common Stock

CalciMedica's CEO, Rachel Leheny, recently purchased 1,000 shares of the company's common stock at an average price of $4.1898 per share.

Summary

• On August 27, 2024, Rachel Leheny, CEO of CalciMedica, Inc., acquired 1,000 shares of common stock.
• The purchase was made at a weighted average price of $4.1898 per share.
• The price range for the shares purchased was between $4.20 and $4.27.
• Following the transaction, Ms. Leheny directly owns 110,926 shares of CalciMedica common stock.
• She also has indirect ownership through her spouse and several Valence Investments SPV entities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive signal, but the transaction is relatively small and doesn't provide a strong indication of future performance.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. Purchases are generally viewed more favorably than sales.

Stakeholder Impact

• The CEO's stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates